<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ORLISTAT</span><br/>(or'li-stat)<br/><span class="topboxtradename">Xenical<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">anorectant</span>; <span class="classification">nonsystemic lipase inhibitor</span><br/><b>Prototype: </b>Diethylpropion<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>120 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Nonsystemic inhibitor of gastrointestinal lipase. Reduces intestinal absorption of dietary fat by forming inactive enzymes
         with pancreatic and gastric lipase in the GI tract.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by weight loss/decreased body mass index (BMI). Reduces the intestinal absorption of dietary fat because at least
         95% of orlistat is eliminated in the feces; reduces caloric intake in obese individuals.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Weight loss and weight maintenance in patients with BMI <img src="../images/special/greaterorequal.gif"/>30 kg/m<sup>2</sup> or <img src="../images/special/greaterorequal.gif"/>27 kg/m<sup>2</sup> in patients with other risk factors. Reduce risk for weight regain after prior weight loss.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to orlistat; malabsorption syndrome; cholestasis; gallbladder disease; hypothyroidism; organic causes of
         obesity; anorexia nervosa, bulimia nervosa; organic causes of obesity, lactation. Safety and efficacy in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Gastrointestinal diseases including frequent diarrhea; known dietary deficiencies in fat soluble vitamins (i.e., A, D, E);
         history of calcium oxalate nephrolithiasis or hyperoxaluria; older adults; pregnancy (category B).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Weight Loss</span><br/><span class="rdage">Adult/Adolescent:</span> <span class="rdroute">PO</span> <i>&gt;16 y,</i> 120 mg t.i.d. with each main meal containing fat<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give during or up to 1 h after a meal containing fat.</li>
<li>Omit dose with nonfat-containing meal or if meal is skipped.</li>
<li>Store at 15°30° C (59°86° F). Keep bottle tightly closed; do <b> <small>NOT</small> </b> use after the printed expiration date.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue. <span class="typehead">CNS:</span> <span class="speceff-common">Headache,</span> dizziness, anxiety. <span class="typehead">CV:</span> Hypertension, stroke. <span class="typehead">GI:</span> <span class="speceff-common">Oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation,</span> fecal incontinence, <span class="speceff-common">abdominal pain/discomfort,</span> nausea, infectious diarrhea, rectal pain/discomfort, tooth disorder, gingival disorder, vomiting. <span class="typehead">Skin:</span> Rash. <span class="typehead">Urogenital:</span> Menstrual irregularity. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Orlistat</b> may increase absorption of <b>pravastatin;</b> may decrease absorption of fat soluble <span class="classification">vitamins</span> (A, D, E, K). Monitor PT/INR inpatients on chronic stable doses of <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Minimal absorption. <span class="typehead">Metabolism:</span> Metabolized in gastrointestinal wall. <span class="typehead">Elimination:</span> Excreted in feces. <span class="typehead">Half-Life:</span> 12 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor weight &amp; BMI; closely monitor diabetics for hypoglycemia.</li>
<li>Coadministered drugs: Monitor PT/INR with warfarin.</li>
<li>Monitor BP frequently, especially with preexisting hypertension.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take a daily multivitamin containing fat-soluble vitamins at least 2 h before/after orlistat.</li>
<li>Remember common GI adverse effects typically resolve after 4 wk therapy.</li>
<li>Avoid high fat meals to minimize adverse GI effects. Distribute fat calories over three main meals daily.</li>
<li>Monitor weight several times weekly. Diabetics: Monitor blood glucose carefully following any weight loss.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>